相似文献
1
Harnessing preclinical mouse models to inform human clinical cancer trials.
J Clin Invest. 2006 Apr;116(4):847-52. doi: 10.1172/JCI28271.
2
Conditional mouse models of cancer.
Handb Exp Pharmacol. 2007(178):263-87. doi: 10.1007/978-3-540-35109-2_11.
3
Using genetically engineered mouse models of cancer to aid drug development: an industry perspective.
Clin Cancer Res. 2006 Sep 15;12(18):5312-28. doi: 10.1158/1078-0432.CCR-06-0437.
4
Preclinical predictors of clinical safety: opportunities for improvement.
Clin Pharmacol Ther. 2007 Aug;82(2):210-4. doi: 10.1038/sj.clpt.6100243. Epub 2007 May 16.
5
Utility of animal models for identification of potential therapeutics for rheumatoid arthritis.
Ann Rheum Dis. 2008 Nov;67(11):1505-15. doi: 10.1136/ard.2007.076430. Epub 2007 Nov 29.
6
New therapeutic advances in the management of progressive thyroid cancer.
Endocr Relat Cancer. 2009 Sep;16(3):715-31. doi: 10.1677/ERC-08-0335. Epub 2009 Feb 13.
7
Improving the evaluation of new cancer treatments: challenges and opportunities.
Nat Rev Cancer. 2003 Apr;3(4):303-9. doi: 10.1038/nrc1047.
8
Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement.
Expert Opin Drug Discov. 2012 Nov;7(11):1093-106. doi: 10.1517/17460441.2012.722077. Epub 2012 Sep 24.
9
Nanoparticle therapeutics: an emerging treatment modality for cancer.
Nat Rev Drug Discov. 2008 Sep;7(9):771-82. doi: 10.1038/nrd2614.
10
Biological surrogate end-points in cancer trials: potential uses, benefits and pitfalls.
Eur J Cancer. 2005 Jun;41(9):1261-6. doi: 10.1016/j.ejca.2005.03.002.
引用本文的文献
1
An Overview of Optic Pathway Glioma With Neurofibromatosis Type 1: Pathogenesis, Risk Factors, and Therapeutic Strategies.
Invest Ophthalmol Vis Sci. 2024 Jun 3;65(6):8. doi: 10.1167/iovs.65.6.8.
2
Studying intramuscular fat deposition and muscle regeneration: insights from a comparative analysis of mouse strains, injury models, and sex differences.
Skelet Muscle. 2024 May 29;14(1):12. doi: 10.1186/s13395-024-00344-4.
3
Translational research: Bridging the gap between preclinical and clinical research.
Indian J Pharmacol. 2022 Nov-Dec;54(6):393-396. doi: 10.4103/ijp.ijp_860_22.
4
Therapeutic Potential of Certain Terpenoids as Anticancer Agents: A Scoping Review.
Cancers (Basel). 2022 Feb 22;14(5):1100. doi: 10.3390/cancers14051100.
5
Current status of MEK inhibitors in the treatment of plexiform neurofibromas.
Childs Nerv Syst. 2020 Oct;36(10):2443-2452. doi: 10.1007/s00381-020-04731-2. Epub 2020 Jun 30.
6
An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development.
Nat Commun. 2020 Jun 4;11(1):2817. doi: 10.1038/s41467-020-16309-2.
7
Comparative study of preclinical mouse models of high-grade glioma for nanomedicine research: the importance of reproducing blood-brain barrier heterogeneity.
Theranostics. 2020 May 15;10(14):6361-6371. doi: 10.7150/thno.46468. eCollection 2020.
8
Cancer drug development: The missing links.
Exp Biol Med (Maywood). 2019 May;244(8):663-689. doi: 10.1177/1535370219839163. Epub 2019 Apr 8.
9
Novel technique for high-precision stereotactic irradiation of mouse brains.
Strahlenther Onkol. 2016 Nov;192(11):806-814. doi: 10.1007/s00066-016-1014-8. Epub 2016 Jul 11.
10
Early phase clinical trials to identify optimal dosing and safety.
Mol Oncol. 2015 May;9(5):997-1007. doi: 10.1016/j.molonc.2014.07.025. Epub 2014 Aug 14.
本文引用的文献
1
Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.
Blood Rev. 2006 Jan;20(1):29-41. doi: 10.1016/j.blre.2005.01.008. Epub 2005 Mar 2.
2
Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.
Development. 2005 Dec;132(24):5577-88. doi: 10.1242/dev.02162.
3
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
N Engl J Med. 2005 Nov 10;353(19):2012-24. doi: 10.1056/NEJMoa051918.
4
Establishment of a serum tumor marker for preclinical trials of mouse prostate cancer models.
Clin Cancer Res. 2005 Nov 1;11(21):7911-9. doi: 10.1158/1078-0432.CCR-05-0953.
5
BRAF mutation predicts sensitivity to MEK inhibition.
Nature. 2006 Jan 19;439(7074):358-62. doi: 10.1038/nature04304. Epub 2005 Nov 6.
6
Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development.
Cancer Res. 2005 Sep 15;65(18):8166-73. doi: 10.1158/0008-5472.CAN-05-1650.
7
A mouse model recapitulating molecular features of human mesothelioma.
Cancer Res. 2005 Sep 15;65(18):8090-5. doi: 10.1158/0008-5472.CAN-05-2312.
8
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.
Cancer Cell. 2005 Aug;8(2):119-30. doi: 10.1016/j.ccr.2005.07.004.
9
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
Nature. 2005 Aug 11;436(7052):807-11. doi: 10.1038/nature03845.
10
Neurogenic tumors in rats induced by ethylnitrosourea.
Exp Toxicol Pathol. 2005 Aug;57(1):7-14. doi: 10.1016/j.etp.2005.04.001.
Zotero 插件